AcuCort has decided to bring forward the publication date of the interim report for the second quarter to August 31, 2023. The report was scheduled to be published on August 11, 2023.
The reason why the publication date has been moved forward is that AcuCort has changed supplier of financial reporting system, which implied new routines that delayed the work of compiling the report. Because of this, the company needs additional time to complete the interim report, and the board has therefore decided to change the date for publication to August 31, 2023.
For further information please contact:
Jonas Jönmark, vd, AcuCort AB
Telefon: 070 365 5400
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. All in all, it strengthens the company’s assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.